Market Place
Sourcing Support
Eisai`s Biologic Leqembi Receives Suppl Approval in US
14 Nov 2024 //
FDA
BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival
02 Jul 2024 //
FIERCE BIOTECH
Eisai and Biogen launch Alzheimer`s drug Leqembi in China
28 Jun 2024 //
REUTERS
Eisai supports creation of Alzheimer’s podcast miniseries
12 Apr 2024 //
FIERCE PHARMA
EU regulator delays decision on Eisai-Biogen Alzheimer`s drug
23 Mar 2024 //
REUTERS
LEQEMBI Approved for the Treatment of Alzheimer’s Disease in China
10 Jan 2024 //
PRESS RELEASE
Eisai`s Biologic Leqembi (lecanemab-irmb) Receives Approval in U.S.
06 Jan 2023 //
FDA
Eisai Satisfies All-Case Study Requirement For Antiepileptic Agent Inovelon
02 Nov 2022 //
EISAI
Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate
11 Sep 2022 //
PRNEWSWIRE
Merck & Eisai Provide Update on Phase 3 LEAP-002 Trial
03 Aug 2022 //
BUSINESSWIRE
Eisai: MHLW Grants ODD in Japan to Mecobalamin Ultrahigh-Dose Formulation
27 May 2022 //
ASIAONE
Japan launches new treatment for chronic constipation
25 May 2022 //
BIOSPECTRUMASIA
Alzheimer drugmakers seek accelerated FDA review despite U.S. coverage decision
09 Apr 2022 //
REUTERS
Latest lecanemab data to be presented at the AD/PD congress
11 Mar 2022 //
PRNEWSWIRE
Biogen and Eisai report Phase III data for Aduhelm in Alzheimer’s disease
13 Nov 2021 //
CLINICALTRIALSARENA
Merck and Eisai Receive +ve EU CHMP Opinions for KEYTRUDA Plus LENVIMA in Cancer
15 Oct 2021 //
BUSINESSWIRE
H3 Biomedicine Presents Update on Intratumoral E7766 Clinical Program
08 Oct 2021 //
BUSINESSWIRE
Eisai files, and the sellside endorses the Alzheimer’s opportunity
28 Sep 2021 //
EVALUATE
Humira bags Japanese additional approval for high-dose regimen of UC
28 Sep 2021 //
PHARMABIZ
Japan Drugmaker Seeks Fast U.S. Approval for Another Alzheimer’s Drug
27 Sep 2021 //
BNNBLOOMBERG
Late-Breaking AAIC Presentation Explore Potential Clinical Effects Of Lecanemab
29 Jul 2021 //
PRNEWSWIRE
Eisai Alzheimer Disease Pipeline Research, New Lecanemab Data, to 2021 AAIC
22 Jul 2021 //
PRNEWSWIRE
Eisai Alzheimer Disease Pipeline Research, New Lecanemab Data, to 2021 AAIC
22 Jul 2021 //
PRNEWSWIRE
BMS-Eisai, China price cuts, AZ-Hutchmed—Fierce Pharma Asia
25 Jun 2021 //
FIERCEPHARMA
Investors, patients await FDA decision on Biogen Alzheimer’s drug due Monday
05 Jun 2021 //
REUTERS
EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING
18 May 2021 //
EISAI
Eisai Announces Real-World Data on the Effectiveness of HALAVEN®
18 May 2021 //
PRNEWSWIRE
Eisai Data at ASCO 2021 Highlight Breadth of Oncology Portfolio Across Various
17 May 2021 //
PRNEWSWIRE
EISAI AND NATIONAL CANCER CENTER COMMENCE JOINT RESEARCH
14 May 2021 //
PRESS RELEASE
Merck kidney and uterus cancer treatments granted priority review by FDA
07 May 2021 //
PHARMAFILE
Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA®
29 Apr 2021 //
PRNEWSWIRE
Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA® (lenvatinib
29 Apr 2021 //
PRNEWSWIRE
Boosting Biogen`s Alzheimer`s contender by unclogging the brain
29 Apr 2021 //
FIERCE BIOTECH
Eisai: Application Submitted for Additional Indication Anti Cancer Agent Lenvima
23 Apr 2021 //
ACNNEWSWIRE
Eisai Presents Breadth of Data Across Neurology , Including Alzheimer`s
16 Apr 2021 //
PRNEWSWIRE
KYORIN, Eisai enter license agreement to develop and market Vibegron
31 Mar 2021 //
PHARMABIZ
Eisai`s Anti Cancer agent Lenvatinib-Pembrolizumab combo receives EMA in Japan
30 Mar 2021 //
BIOSPECTRUMASIA
Eisai`s Anti Cancer agent Lenvatinib-Pembrolizumab combo receives EMA in Japan
29 Mar 2021 //
BIOSPECTRUMASIA
Eisai Begins Construction of New Injection/Research Building
22 Mar 2021 //
CONTRACTPHARMA
Eisai Medicine Innovation Technology Solutions to launch in Japan
22 Mar 2021 //
BIOSPECTRUMASIA
Merck, Eisai detail Keytruda-Lenvima confirmatory trial win
19 Mar 2021 //
FIERCEPHARMA
Merck, Eisai detail Keytruda and Lenvima`s endometrial cancer win in study
19 Mar 2021 //
FIERCEPHARMA
Eisai to support construction of coronavirus screening framework in Kenya
03 Mar 2021 //
BIOSPECTRUMASIA
Eisai’s anti-insomnia drug, Dayvigo gets approval in Hong Kong
02 Mar 2021 //
PHARMABIZ
Merck, Eisai turn up the heat in kidney cancer with survival win
16 Feb 2021 //
FIERCE PHARMA
Eisai launches Parkinson`s disease treatment Equfina in South Korea
02 Feb 2021 //
BIOSPECTRUMASIA
FDA extends review period for Biogen`s Alzheimer`s drug to June
30 Jan 2021 //
REUTERS
Biogen seeks Japanese approval for aducanumab to treat Alzheimer’s disease
10 Dec 2020 //
PHARMABIZ
#ThisIsMBC Perseverance Campaign from Eisai and METAvivor Captures the Joys
08 Dec 2020 //
PRNEWSWIRE
AbbVie, Eisai receives approval for additional indication of Humira
27 Nov 2020 //
PHARMABIZ
Biogen Alzheimer`s drug gets FDA staff backing, shares jump 40%
06 Nov 2020 //
REUTERS
Eisai to Present Latest Alzheimer`s Disease Pipeline Research CTAD 2020 BAN2401
02 Nov 2020 //
PRNEWSWIRE
Eisai builds health service platform for elders in China
28 Oct 2020 //
BIOSPECTRUMASIA
EISAI TO PRESENT LATEST DATA PIPELINE ASSETS IN THE AREA OF ALZHEIMER’S DISEAS
28 Oct 2020 //
PRESS RELEASE
Eisai, Cogstate expand pact for development & commercialization of digital
26 Oct 2020 //
PHARMABIZ
Eisai doubles down on Cogstate digital cognitive tool pact
26 Oct 2020 //
FIERCEBIOTECH
China NMPA accepts Eisai’s sNDA for anti-epileptic drug Fycompa as monotherapy
16 Oct 2020 //
PHARMABIZ
University of Tokyo and Eisai ink research collaboration to discover
09 Oct 2020 //
PHARMABIZ
Eisai, Seikagaku ink marketing agreement for osteoarthritis drug in South Korea
02 Oct 2020 //
BIOSPECTRUMASIA
Eisai Initiates Phase 3 MOMENTUM 1 Clinical Trial (Study 304) of Lorcaserin
30 Sep 2020 //
PRNEWSWIRE
